Please login to the form below
IBS
This page shows the latest IBS news and features for those working in and with pharma, biotech and healthcare.
Latest news
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Roche added that it will continue to follow up with patients in the Impower010 study, with planned analyses of DFS in the overall intent-to-treat population, including stage IB patients,
-
Ardelyx gets second kidney disease trial win for tenapanor
Shares in Ardelyx rocketed 72% on the back of the new study on the prospect of a second indication for tenapanor to follow constipation associated with IBS, which is under review
-
China approves Ironwood Pharma’s IBS treatment
Approval by China’s NMPA for adults with irritable bowel syndrome with constipation (IBS-C) opens up the country's huge market to the treatment. ... This approval is incredibly important as it brings a new option to treat some of the bothersome
-
China’s Innovent to start US trials of anti-CD47 cancer drug
Innovent reckons IB-188 has stronger receptor blocking ability than other investigational drugs against CD47, and says it intends to start several clinical trials across multiple cancers, including non-Hodgkin's
-
FDA awards another non-opioid pain drug breakthrough status
The Breakthrough Therapy designation is based on phase Ib placebo-controlled clinical trial in patients undergoing bunionectomy.
More from news
Approximately 4 fully matching, plus 96 partially matching documents found.
Latest Intelligence
-
Erectile dysfunction, constipation, vaginal dryness and other laughing matters
An Irritable Bowel Syndrome campaign tackled the challenge of IBS not being taken seriously by actually using humour. ... However, FiberOne poked fun at doctors and their scepticism of the legitimacy of IBS.
-
Holding on to hope for Alzheimer’s advances
Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Positive results from a phase Ib dose-escalation study were
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Deal Watch January 2016
TEN-010, the lead, is a small molecule BET inhibitor that is in two phase Ib oncology studies. ... It is expected that $30m of payments will fall in 2016 relating to the phase Ib studies for SER 262 and a late stage study for SER 109 in CDI.
-
Pharma deals in February 2015
diarrhoea (IBS-D) label be successful, this figure could rise to $2bn.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Voyager Therapeutics appoints chief financial officer
This strong foundation combined with the company's recent positive interim phase Ib data from its lead program VY-AADC01 for advanced Parkinson's disease and the opportunity to join a
-
Boyds appoints Dr Nick Meyers and Natasha Nesterova-Smith
where he was responsible for the development of treatment of IBS-C and IBS-A.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Diagnosing MS: are we getting it right?
MS symptoms can be hard to pin down. I’ve heard bladder issues being attributed to “women’s problems”, bowel issues to irritable bowel syndrome (IBS), and fatigue to stress and
-
Irritable Bowel Syndrome (IBS) patient insights
underestimate the severity of IBS symptoms . understate global effect on quality of life . ... 1). "IBS is a real gastrointestinal condition; it is not ‘in your head’.".
-
IGNIFI
Irritable Bowel Syndrome (IBS) patient insights. ... It’s common. It’s debilitating. We’re talking about IBS. In this issue of MAGNIFI, we explore the insights of patients suffering with IBS, while also looking into research around
-
Shifting perceptions of the use of probiotics in IBS Management
Our client was planning to launch an over-the-counter (OTC) probiotics product for the purposes of improving IBS management and wanted to understand current perceptions, practices and usage amoungst a
-
PEGASUS WINS COMMUNIQUÉ 2015 ‘EXCELLENCE IN PATIENT/CONSUMER HEALTH PROGRAMMES’ AWARD FOR RARE DISEASE AWARENESS CAMPAIGN
Communications’ award for their ‘Managing IBS Better Together’ campaign for Boehringer Ingelheim.
More from PMHub
Approximately 2 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
Spirit, an OPEN Health Company
We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
